Intervention Protocol

Intravenous immunoglobulin for juvenile idiopathic arthritis

  1. Julio Cesar Orellana1,*,
  2. Ramon E Pogonza2,
  3. Maria Angeles Lopez-Olivo3,
  4. Aimee Kendall Roundtree4,
  5. Zulma Ortiz5

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 18 OCT 2006

DOI: 10.1002/14651858.CD006191

How to Cite

Orellana JC, Pogonza RE, Lopez-Olivo MA, Roundtree AK, Ortiz Z. Intravenous immunoglobulin for juvenile idiopathic arthritis (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006191. DOI: 10.1002/14651858.CD006191.

Author Information

  1. 1

    Cordoba, Cordoba, Argentina

  2. 2

    Hospital de Ninos de la Santisima Trinidad, Area de Produccion Cientifica, Cordoba, Argentina

  3. 3

    The University of Texas, M.D. Anderson Cancer Center, General Internal Medicine, Ambulatory Treatment and Emergency Care, Houston, Texas, USA

  4. 4

    University of Houston - Downtown, Houston, Texas, USA

  5. 5

    National Academy of Medicine, Epidemiological Research Center, Buenos Aires, Federal Capital, Argentina

*Julio Cesar Orellana, Lavalleja 1160, Cordoba, Cordoba, 5000, Argentina.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 OCT 2006




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The aim of this review is to determine the clinical effectiveness and safety of intravenous immunoglobulin for JIA.

This review will address two core questions:

1. What is the clinical efficacy of intravenous immunoglobulin for the treatment of JIA in terms of controlling the disease and reducing joint counts?

2. What are the risks (frequency and severity of adverse events) associated with immunoglobulin treatment in these patients?